NUC-3373 for colorectal cancer - Clinical Trial

What is the Purpose of this Study?

If you choose to join this study, you will:
- Get NUC-3373 by IV every 1 or 2 weeks
- Get chemotherapy and/or bevacizumab every 2 weeks
- Give blood and urine samples
- Have regular CT or MRI scans

What is the Condition Being Studied?

Colorectal Cancer

Who Can Participate in the Study?

Adults with colorectal cancer who:
- Have locally advanced, unresectable, or metastatic disease
- Have already received at least 1 line of treatment

For more information about who can join this study, please contact the study team at

Age Group

What is Involved?

We are doing this study to see if the study drug, NUC-3373, is safe and effective for treating colorectal cancer when combined with existing therapies.

Study Details

Full Title
[Nutide302] A Phase Ib/II open label study to assess the safety and pharmacokinetics of NUC-3373, a nucleotide analogue, given in combination with standard agents used in colorectal cancer treatment
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00109258
NCT: NCT03428958
Phase I/II
Enrollment Status
Open for Enrollment
Contact the Duke Recruitment Innovation Center